by Kevin Dooley, MD | Mar 30, 2021 | News and Information
Negative Results The biotech company Orphazyme announced negative results yesterday for the clinical trial of arimoclomol in the treatment of inclusion body myositis (IBM). The drug failed to meet the primary and secondary endpoints which were used to measure success.... 
by Kevin Dooley, MD | Aug 26, 2020 | News and Information
The Orphan Disease Center 2020 Million Dollar Bike Ride Grant Program is offering a $68,245 grant for the study of inclusion body myositis (IBM). Researchers from around the world are eligible to apply. Letters of Interest are due Friday, September 18. The grant is... 
by Kevin Dooley, MD | Jun 10, 2020 | News and Information
JOIN US! On June 13, you can support the cause of inclusion body myositis by biking, walking, running, swimming, or riding in your own town or city. The Million Dollar Bike Ride has become a virtual event this year. Although it is unfortunate that Team Cure IBM cannot... 
by Kevin Dooley, MD | Apr 14, 2020 | News and Information
Due to the coronavirus pandemic, Team Cure IBM will not be able to ride our bikes in Philadelphia this summer. However, although the University of Pennsylvania, the sponsor of the Million Dollar Bike Ride (MDBR), has cancelled the ride, the MDBR will still continue as... 
by Kevin Dooley, MD | Mar 19, 2020 | News and Information
AAVogen, an early-stage biotech company, is developing a new treatment for inclusion body myositis (IBM). AVGN7 is a novel gene therapy treatment that is designed to treat IBM and other muscle wasting conditions. AAVogen has raised $2.3 million to date, mostly from... 